Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
|Articles|September 17, 2020
Quiz: Incidence of Colorectal Cancer
Author(s)Hannah Slater
In our colorectal cancer quiz, you’ll get a chance to test your knowledge on the incidence of colorectal cancer and the risk factors associated with the disease.
Advertisement
1. How common is colorectal cancer as a cause of cancer death?
a. It is the third leading cause
b. It is the fifth leading cause
c. It is the tenth leading cause
d. It is the fourth leading cause
Advertisement
Related to this article
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5